Objective: To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children.
Introduction
Antiretroviral drugs have changed HIV-1 infection from a life-threatening disease to a chronic infection. However, adherence to therapy remains a key determinant of disease outcome. For perinatally HIV-infected children, who face a lifetime on treatment, maintaining long-term adherence is often a challenge. Simplification of treatment, including decreasing the frequency of dosing, is likely to increase convenience and enhance adherence to antiretroviral therapy (ART) [1] . Although several q.d. regimens have been shown to have noninferior efficacy and safety in adults [2] , resulting in Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval and widespread use in clinical practice, fewer antiretroviral drugs are licensed to be taken q.d. by children.
Protease inhibitors are potential candidates for q.d. dosing. They have a high genetic barrier to development of resistance [3] and when coadministered with ritonavir, resulting in increased absorption and/or prolonged terminal elimination half-life, have increasing potential for decreased dosing frequency. The coformulation of ritonavir-boosted lopinavir (lopinavir/r) in one tablet (also available as a smaller paediatric formulation) also enhances convenience of dosing. Various studies have supported the licensing of q.d. dosing of lopinavir/r for HIV-infected adults [2, [4] [5] [6] [7] . However, based on the currently available evidence in children, paediatric treatment guidelines recommend lopinavir/r to be taken twice daily (b.i.d.) [8, 9] . Small studies using q.d. lopinavir/r oral solution or soft gel capsules in children showed high interpatient variability in lopinavir pharmacokinetic parameters and low trough levels [10, 11] . Reduced variability in lopinavir pharmacokinetic in adults and children has been observed after administration of the tablet formulation, suggesting that this formulation could be more appropriate for q.d. dosing [12, 13] . Here we report the results of KONCERT (PENTA18/ ANRS150), the first randomized controlled trial evaluating the safety, efficacy and pharmacokinetic of lopinavir/r tablets dosed q.d. vs. b.i.d. following FDA body-weight band dosing guidelines in virologically suppressed ART-experienced children and adolescents.
Methods

Study design and participants
KONCERTwas an open-label, multicentre, randomized trial (ISRCTN 02452400, EudraCT 2009-013648-35) in HIV-infected children aged below 18 years who had a stable CD4 þ cell count on combination ART containing b.i.d. lopinavir/r and had been virologically suppressed (viral load <50 copies/ml) for at least 24 weeks (single viral load <400 copies/ml allowed). In addition, eligibility required that children had viral load less than 50 copies/ml at screening, weighed !15 kg and were able to swallow tablets. Kaletra tablets were used throughout. If required, lopinavir/r dose was adjusted at screening in line with the US FDA dosing guidelines based on bodyweight band [total daily dose: 400/100 mg lopinavir/r (15 to 25 kg), 600/150 mg (25 to 35 kg) or 800/200 mg (>35 kg)] [14] . Children were randomized 1 : 1 to continue taking lopinavir/r b.i.d. or to take their total daily lopinavir/r in a single dose. Parents/guardians and adolescents provided written consent, younger children gave assent according to their age and knowledge of HIV status. The study received approval from ethics committees and regulatory bodies in each participating country and clinical site.
Randomization was stratified by weight band (as above) and participation in the pharmacokinetic substudy. The computer-generated sequentially numbered randomization list (with variable block sizes) was preprepared by the trial statistician and securely incorporated within the database at the Trials Unit. Randomization was undertaken via a web service accessed by the clinician or Trials Unit, who could access the next allocation but not the whole list.
Outcome measures
The primary endpoint was a viral load at least 50 copies/ ml (confirmed within 4 weeks) within the first 48 weeks of follow-up. Primary endpoints for the pharmacokinetic substudies were pharmacokinetic parameters of lopinavir/r [area under the curve (AUC), C max , [1] has previously been described [15] . Secondary outcomes included the following: viral load at least 400 copies/ml (confirmed) within 48 weeks; number of major HIV-1 RNA mutations in those with viral rebound; change in CD4 þ cell count/percentage from baseline to 48 weeks; adherence to, acceptability of, and changes made to the ART regimen; ART-related grades 3 and 4 clinical or laboratory adverse events [16, 17] .
Data collection and follow-up procedures
Follow-up visits were scheduled at weeks 4, 8 and 12, then 12 weekly until the last child reached week 48 (Fig. 1 ). Viral load was measured at each study visit; children with viral load at least 50 copies/ml returned within 4 weeks for retest of viral load. Assessment of adherence to treatment and a resistance test were requested when children had a confirmed viral load at least 50 copies/ml. T-cell lymphocyte subsets were performed at all visits; biochemistry and haematology were performed 12-weekly; blood lipids were measured at weeks 0, 24 and 48; adherence questionnaires were given to carers and children at weeks 0, 4, 12, 24 and 48; acceptability questionnaires were completed at baseline and if children switched from q.d. to b.i.d. dosing. At each study visit, a plasma sample was stored for subsequent assessment of population lopinavir/r pharmacokinetic.
Pharmacokinetic substudy
Children who consented were enrolled in a pharmacokinetic substudy, until a minimum of 16 children in each stratification weight band had evaluable pharmacokinetic data. Children with nonevaluable pharmacokinetic results were followed within the main study, but excluded from the pharmacokinetic analysis. Lopinavir pharmacokinetics were determined at week 0 in both arms, and at week 4 if randomized to q.d. dosing. Prior to the day of pharmacokinetic assessment, children took the paediatric lopinavir/r tablet (100/25 mg) formulation for at least seven days, following the FDA-recommended weight band-based dosing. On the pharmacokinetic assessment day, 2 ml of blood was taken before observed intake of lopinavir/r in the morning (t ¼ 0) and at 2, 4, 6, 8 and 12 (week 0, b.i.d.) or 24 h (week 4, q.d.) after the dose. Plasma concentrations were determined using a validated ultrahigh performance liquid chromatography assay with UV detection derived from a previously published assay [18] . Lopinavir pharmacokinetic parameters were determined using noncompartmental analysis (WinNonlin/ Phoenix version 6.3; Pharsight Corporation, Mountain View, California, USA): AUC 0-24 [area under the plasma concentration-time curve calculated (linear up-log down method) over a dosing interval from time 0 to 24 h after dosing], C max (maximum observed plasma concentration), T max (time of maximum observed plasma concentration), C last (last observed drug concentration) and clearance (CL/F). The intensive pharmacokinetic analyses were performed at the Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
Lopinavir concentrations were also determined on available stored plasma samples at the screening visit and at weeks 0, 4, 8, 12, 24, 36 and 48 on all children. This was done to investigate the effect of having lopinavir plasma concentration below the lower limit of quantification (LLOQ ¼ 0.10 mg/l) at any visit on virological rebound. Pharmacokinetic analyses for these stored samples were performed at Radboud University Medical Center, except for samples in Thailand which were performed at the PHPT-AMS laboratory, Chiang Mai University, Thailand. Both laboratories participate in an international interlaboratory quality control programme for therapeutic drug monitoring of antiretroviral drugs [19] . Statistical analyses A target enrolment of 160 children (80 in each arm) provided at least 80% power to exclude a noninferiority margin of 12% for the difference between the two arms in the proportion of children reaching the primary endpoint, assuming a 10% virological rebound rate and onesided a ¼ 0.05. An Independent Data Monitoring Committee reviewed interim data for safety and efficacy three times during the study.
All comparisons between randomized arms (q.d. vs. b.i.d.) were intention-to-treat, with follow-up censored at week 52 or last follow-up date (if before the week 48 visit). The proportion of children experiencing virological rebound by week 48 in each arm was estimated using the Kaplan-Meier method, with 90% confidence intervals (CIs) for the difference in proportions calculated using bootstrap standard errors [20] . Two prespecified sensitivity analyses of the primary outcome were completed: adjusting for baseline stratification factors, and censoring follow-up at the time of lopinavir/r treatment modification (change in dose, >7-day interruption or permanent discontinuation; a 'per-protocol' analysis). A post-hoc analysis adjusting for chance imbalance between arms in viral load and CD4% at baseline was also performed.
Change in CD4% and other continuous laboratory outcomes from baseline to 48 weeks were analyzed using normal regression, adjusting for the baseline measurement and stratification factors. Major resistance mutations known to confer resistance to antiretroviral drugs not seen in any pretrial resistance tests were summarized by drug class. Categorical variables were compared using Fisher's exact tests; rates were estimated using Poisson regression. All P values were two sided and all statistical calculations were performed using STATA (Stata Statistical Software, Release 13; StataCorp LP, College Station, Texas, USA). An overall geometric mean ratio (GMR) for each pharmacokinetic parameter was calculated after log-transformation of the within-subject ratios; 90% CIs were calculated (using the t-distribution) using the bioequivalence crossover design tool approach within the Phoenix WinNonlin software package (with fixed effects in the model specification). A GMR with a 90% CI including 1.0 and falling entirely within 0.80-1.25 was considered as bioequivalence for AUC 0-24 and C max . Relative risk ratios were calculated comparing the likelihood of virological rebound for children with at least one sample with lopinavir concentration levels below LLOQ to those children with all samples ! LLOQ.
Results
Baseline characteristics
Between August 2010 and August 2012, 173 children were randomized (86 allocated to q.d., 87 to b.i.d.) (Fig. 1) ; 80 children from Europe, 59 from Thailand and 34 from South America; participants were from 49 clinical centres in 12 countries. Fifty-three took part in the pharmacokinetic substudy, 27 randomized to the q.d. arm; 46, 50 and 77 children were in the 15 to 25kg, >25 to 35kg, >35kg weight bands, respectively.
Baseline demographics were similar in the two arms (Table 1) ; median (IQR) age was 11.0 (8.7, 14.3) years and 94 (54%) were female. More children in the q.d. arm had advanced HIV disease, lower CD4% and a viral load at least 50 copies/ml at baseline (Table 1 ). Pretrial ART exposure was comparable between arms; 35 (20%) children were on their first-line regimen at baseline, and half had been exposed to three different antiretroviral drug classes. The children were on a variety of NRTI backbones at baseline (44% zidovudine þ lamivudine or emtricitabine, 20% abacavir þ lamivudine or emtricitabine, 16% tenofovir þ any other NRTI, 20% other); 29% of backbone NRTIs were taken as q. (Fig. 2) . The upper 90% confidence limit of 14% was greater than the predefined noninferiority margin of 12%.
Results were similar after adjustment for stratification factors -estimated difference between arms of 6% [90% CI (-2%, 14%), bootstrap P ¼ 0.20] -and for per-protocol analyses wherein follow-up for eight children was censored as a result of treatment modification -estimated difference between arms of 5% [90% CI (-3%, 13%), bootstrap P ¼ 0.27]. A post-hoc analysis adjusting for the chance imbalance between arms in viral rebound at baseline, reduced the estimated difference in proportion rebounding to 4% [90% CI (-4, 11%), bootstrap P ¼ 0.39], bringing the upper 90% confidence limit just within the noninferiority margin. discontinued lopinavir/r after rebound (both resuppressed).
Secondary outcomes Viral rebound defined as at least 400 copies/ml was observed in 11 children (eight q.d., three b.i.d.); the estimated difference between arms in the probability of rebounding by 48 weeks was 6% [90% CI (0, 12%),
Genotypic resistance tests were available in 18 ( There were no significant differences between the trial arms for any of the clinical safety endpoints (Table 2) . 18 (21) 17 (20) 35 (20) Exposed to three classes of ART: n (%)
41 (48) 46 (53) 87 (50) a All <50 copies/ml at screening. concentration <LLOQ was 7.61 (2.95, 19.69). A trend was observed of an increasing proportion experiencing virological rebound when the number of samples with concentrations <LLOQ increased: 5.5% with no samples <LLOQ, 21.4% with one sample <LLOQ and 57.1% with two or more samples <LLOQ.
Discussion
KONCERT is the first randomized controlled trial in children and adolescents to investigate the safety and efficacy of q.d. vs. b.i.d. dosing of lopinavir/r. Children from a wide age-range were included, and all main ethnic [10] [11] [12] [22] [23] [24] [25] . In our larger study, the AUC was at the lower end of this range and C last below it. This cannot be explained by lower dose, as the median lopinavir dose received by children in the pharmacokinetic study was 19.0 mg/kg or 537 mg/m 2 q.d., which is comparable or higher than the doses received by children in the other studies. In addition, exposure to lopinavir from tablets in adults was shown to be significantly higher than from softgel capsules, although the 90% CI of the GMR was reported to be within the bioequivalence range [13] .
Additional findings from this trial reflect 'real life' dosing, as not only were formal 'within-child' pharmacokinetic studies undertaken, but also sparse random sampling in all children attending clinic throughout the 48 weeks. We demonstrated that more children in the q.d. treatment group had at least one undetectable (<LLOQ) lopinavir plasma concentration: 24.4% q.d. vs. 8.0% b.i.d. Further we observed a pharmacokinetic/pharmacodynamics relationship, with the overall risk of viral load rebound being over seven-fold greater among children with at least one lopinavir concentration <LLOQ, and twice as high in q.d. vs. b.i.d. children (9.3 vs. 4.6) . These findings together with the results of the within-child pharmacokinetic show that lopinavir is less forgiving when children are dosed q.d., and thus if children are nonadherent, there is a higher chance of virological rebound. Despite this during the trial, nine out of 12 children on q.d. who rebounded later resuppressed, and seven of the nine remained on q.d. lopinavir/r. Although drug concentration measurements demonstrated that missed q.d. doses had a greater risk of viral rebound, reassuringly due to the relatively high resistance barrier of ritonavir-boosted lopinavir, development of new mutations remained low, and similar to b.i.d. dosing.
Both children and carers reported a preference for taking lopinavir/r q.d., but data from the adherence questionnaires suggests that a small number of children may miss more doses on q.d.
In resource-rich countries, other q.d. boosted protease inhibitor treatments are now widely available for children, but in resource poor situations, which carry the burden of the epidemic, lopinavir/r remains the mainstay of paediatric protease inhibitor based therapy (Habiyambere V, WHO ARV use survey, 2014, personal communication) [26] , and the findings of the trial are particularly relevant to these settings.
In conclusion, based on the combination of viral load rebound and pharmacokinetic results in the KONCERT trial, q.d. lopinavir/r cannot be routinely recommended as a simplification option for children with suppressed viral load on b.i.d. lopinavir/r. However, among selected adherent children for whom regular viral load monitoring is available, q.d. dosing remains an option, as we have demonstrated that it is both safe and not associated with any increased risk of developing resistance mutations. the writing of the manuscript, and read and approved the final version.
